AI Target Identification: A novel approach to drive drug R&D in IPF?

  Within the realm of lung diseases, developing new drugs to treat Idiopathic Pulmonary Fibrosis (IPF) remains a formidable challenge. Characterized by progressive scarring of lung tissue, IPF significantly impairs breathing and has a median survival rate of just 2 to 3 years post-diagnosis. Current therapeutic options are limited, often providing only marginal relief while […]

First drug approval in NASH

NASH TherapeutAix

When we reviewed the R&D landscape in nonalcoholic steatohepatitis (NASH) in 2018, we highlighted 4 development programs that were in Phase 3 development and all targeting pivotal data readout, and a potential launch, between 2019 and 2021. However, obeticholic acid, elafibranor, cenicriviroc, and selonsertib all turned out to not confirm their initial positive data in […]

How rare diseases came to be defined: Rare Disease Day 2024

rare disease day 2024

Today is Rare Disease Day, an international awareness day that takes place annually on 28th February (or 29th on leap years like this one) – the rarest day of the year. In earlier blogs we looked at the relationship of rare diseases to common diseases, and how thinking about one can benefit thinking about the […]

Exciting news for inhaled lung fibrosis therapies

ipf inhaled therapies

Last year we made a series of posts highlighting the opportunities and challenges of developing inhaled therapies for idiopathic pulmonary fibrosis (IPF). In this blog, we provide an update on the most recent developments in inhaled IPF therapies. To recap the opportunities and challenges, the inhaled route offers the advantage of delivering a medicine directly […]

Did you know that TherapeutAix offer a project management service?

In this role, we provide oversight and co-ordinate activities of providers from within and outside our network to ensure timely and efficient provision of fit for purpose data. We believe that, by bringing the contributors together with regular meetings, we generate a value that is greater than the sum of the parts.   Three projects we […]

New Innovative Partnerships?

Pharma partnerships

Last year, Darcey Black, Director of Translational Science at TherapeutAix, together with colleagues, Gregor MacDonald from Lundbeck and Mo Alavijeh from Pharmidex organised a meeting for the Society of Medicines Research on “Innovative New Pharma and Biotech Partnerships: How is the landscape transforming?  The report of that successful meeting has just been published in Drugs […]

2022: A TherapeutAix Roundup

As the year draws to a close, we wanted to take a look back at our activities throughout 2022, reflecting on the return of in-person events, the advancements in medicine and the successes of our client projects. Here are our top highlights:    Events 2022 saw a welcomed return to in-person events, and we had […]

What’s it like to work with us?

the therapeutaix team laughing and smiling in aachen

What’s it like to work with TherapeutAix, you may ask? While we have quite a bit of information on our website, here’s how a typical client of ours may use us in support of their R&D project.   Initial contact We usually start with an initial video call to get to know each other, understand […]

One Project, Many Customers

In theory, the drug discovery and development pathway is not complicated. You start with an exciting idea where biology meets disease, target a mechanism, and identify and optimise a molecule that can modulate the mechanism to treat the disease. Theoretically, it would work that way if not for different stakeholders expecting different data to justify […]

The Role of Pre-Clinical Bleomycin Models in IPF Drug Development 

In this article, TherapeutAix has come together with one of our partners, OracleBio, a provider of Quantitative Digital Pathology services supporting pharma and biotech R&D, to provide our collective thoughts on the use and value of the pre-clinical bleomycin model in drug development for Idiopathic Pulmonary Fibrosis (IPF).  IPF is a progressive lung disease with […]

We’d like to send you our company updates, invites to events and any other relevant news. By providing your details and subscribing to this list, you are giving us your consent to send you these updates.

We’ll always be mindful of how often we send our updates and you can amend your preferences at any time.

We’ll never sell or swap your data with any organisation and we’ll store your details securely, respecting your trust and privacy. Please view our privacy policy for further details.

Marketing Permissions
Please select all the ways you would like to hear from TherapeutAix:
You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please visit our website.